Direct-to-consumer telehealth company Hims & Hers is defending its sale of compounded glucagon-like peptide agonists, or GLP-1s, even as shortages of the name brand weight loss medications are waning.

Says trajectory in 2024 “nothing short of phenomenal.” Says business trajectory setting “robust foundation” for 2025. Comments taken from Q3 earnings conference call. TipRanks is the most ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4. The move comes as patients ...

Investing.com -- Hims Hers Health Inc (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year guidance, driven by strong subscriber growth and ...

Hims & Hers shares have jumped by over 138% this year. The company published strong financial results on Monday. The stock has formed a double-top pattern, pointing to a short-term pullback.

What should you gift to someone who's picky about their products? Our advice is to curate a gift according to her interests and personality. A gift for the lady in your life should be just that ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...